;PMID: 8669690
;source_file_633.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..162] = [t:44..162]
;2)section:[e:166..197] = [t:166..197]
;3)section:[e:201..315] = [t:201..315]
;4)sentence:[e:319..330] = [t:319..330]
;5)sentence:[e:331..552] = [t:331..552]
;6)sentence:[e:553..717] = [t:553..717]
;7)sentence:[e:719..1105] = [t:719..1105]
;8)sentence:[e:1107..1115] = [t:1107..1115]
;9)sentence:[e:1116..1301] = [t:1116..1301]
;10)sentence:[e:1302..1549] = [t:1302..1549]
;11)sentence:[e:1550..1735] = [t:1550..1735]
;12)sentence:[e:1737..1745] = [t:1737..1745]
;13)sentence:[e:1746..2006] = [t:1746..2006]
;14)sentence:[e:2007..2263] = [t:2007..2263]
;15)sentence:[e:2265..2277] = [t:2265..2277]
;16)sentence:[e:2278..2540] = [t:2278..2540]
;17)section:[e:2544..2588] = [t:2544..2588]
;Token/POS Errors
;ERROR_Token in entity file but not tree[537..538] K
;ERROR_Token in entity file but not tree[538..539] +
;ERROR_Token in entity file but not tree[539..541] Ca
;ERROR_Token in entity file but not tree[1895..1896] K
;ERROR_Token in entity file but not tree[1896..1897] +
;ERROR_Token in entity file but not tree[1897..1899] Ca
;ERROR_POS mismatch [28..29] t:token e:CD 6
;ERROR_Token in tree file but not entity[537..541] K+Ca
;ERROR_Token in tree file but not entity[1895..1899] K+Ca

;section 0 Span:0..38
;Anesthesiology. 1996 Jun;84(6):1485-8.
(SEC
  (FRAG (VBG:[0..14] Anesthesiology) (RB:[14..15] .) (CD:[16..20] 1996)
        (.:[21..26] Jun;8) (CD:[26..27] 4) (NN:[27..28] -LRB-)
        (token:[28..29] 6) (-RRB-:[29..30] -RRB-) (::[30..31] :)
        (CD:[31..34] 148) (CD:[34..37] 5-8) (.:[37..38] .)))

;sentence 1 Span:44..162
;Etomidate and thiopental inhibit the release of endothelium-derived 
;hyperpolarizing factor in the human renal artery.
;[44..53]:substance:"Etomidate"
;[58..68]:substance:"thiopental"
;[92..135]:substance:"endothelium-derived  hyperpolarizing factor"
(SENT
  (S-HLN
    (NP-SBJ (NN:[44..53] Etomidate) (CC:[54..57] and) (NN:[58..68] thiopental))
    (VP (VBP:[69..76] inhibit)
      (NP
        (NP (DT:[77..80] the) (NN:[81..88] release))
        (PP (IN:[89..91] of)
          (NP
            (ADJP (NN:[92..103] endothelium) (HYPH:[103..104] -)
                  (VBN:[104..111] derived))
            (VBG:[113..128] hyperpolarizing) (NN:[129..135] factor))))
      (PP-LOC (IN:[136..138] in)
        (NP (DT:[139..142] the) (JJ:[143..148] human) (JJ:[149..154] renal)
            (NN:[155..161] artery))))
    (.:[161..162] .)))

;section 2 Span:166..197
;Kessler P, Lischke V, Hecker M.
(SEC
  (FRAG (NNP:[166..173] Kessler) (NNP:[174..176] P,) (NNP:[177..184] Lischke)
        (NNP:[185..186] V) (,:[186..187] ,) (NNP:[188..194] Hecker)
        (NNP:[195..197] M.)))

;section 3 Span:201..315
;Center of Anesthesiology and Resuscitation, Johann Wolfgang Goethe University
; Clinic, Frankfurt am Main, Germany.
(SEC
  (FRAG (NNP:[201..207] Center) (IN:[208..210] of)
        (NNP:[211..225] Anesthesiology) (CC:[226..229] and)
        (NNP:[230..243] Resuscitation) (,:[243..244] ,) (NNP:[245..251] Johann)
        (NNP:[252..260] Wolfgang) (NNP:[261..267] Goethe)
        (NNP:[268..278] University) (NNP:[280..286] Clinic) (,:[286..287] ,)
        (NNP:[288..297] Frankfurt) (,:[298..300] am) (NNP:[301..305] Main)
        (IN:[305..306] ,) (NNP:[307..314] Germany) (.:[314..315] .)))

;sentence 4 Span:319..330
;BACKGROUND:
(SENT
  (NP (NN:[319..329] BACKGROUND) (::[329..330] :)))

;sentence 5 Span:331..552
;Endothelium-derived hyperpolarizing factor is thought to be a  cytochrome
;P450-derived arachidonic acid metabolite that hyperpolarizes vascular  smooth
;muscle cells by opening Ca(2+)-activated K+ channels (K+Ca channels).
;[331..373]:substance:"Endothelium-derived hyperpolarizing factor"
;[394..409]:cyp450:"cytochrome P450"
;[418..445]:substance:"arachidonic acid metabolite"
;[507..513]:substance:"Ca(2+)"
;[524..526]:substance:"K+"
;[537..538]:substance:"K"
;[539..541]:substance:"Ca"
(SENT
  (S
    (NP-SBJ-2
      (ADJP (NN:[331..342] Endothelium) (HYPH:[342..343] -)
            (VBN:[343..350] derived))
      (VBG:[351..366] hyperpolarizing) (NN:[367..373] factor))
    (VP (VBZ:[374..376] is)
      (VP (VBN:[377..384] thought)
        (S
          (NP-SBJ-2 (-NONE-:[384..384] *))
          (VP (TO:[385..387] to)
            (VP (VB:[388..390] be)
              (NP-PRD
                (NP (DT:[391..392] a)
                  (ADJP
                    (NML (NN:[394..404] cytochrome) (NN:[405..409] P450))
                    (HYPH:[409..410] -) (VBN:[410..417] derived))
                  
                  (NML (JJ:[418..429] arachidonic) (NN:[430..434] acid))
                  (NN:[435..445] metabolite))
                (SBAR
                  (WHNP-1 (WDT:[446..450] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[450..450] *T*))
                    (VP (VBZ:[451..465] hyperpolarizes)
                      (NP (JJ:[466..474] vascular)
                        (NML (JJ:[476..482] smooth) (NN:[483..489] muscle))
                        (NNS:[490..495] cells))
                      (PP-MNR (IN:[496..498] by)
                        (S-NOM
                          (NP-SBJ (-NONE-:[498..498] *))
                          (VP (VBG:[499..506] opening)
                            (NP
                              (NP
                                (ADJP (NN:[507..513] Ca-LRB-2+-RRB-)
                                      (HYPH:[513..514] -)
                                      (VBN:[514..523] activated))
                                (NN:[524..526] K+) (NNS:[527..535] channels))
                              (NP (-LRB-:[536..537] -LRB-) (NN:[537..541] K+Ca)
                                  (NNS:[542..550] channels)
                                  (-RRB-:[550..551] -RRB-)))))))))))))))
    (.:[551..552] .)))

;sentence 6 Span:553..717
;In  the rabbit carotid artery both volatile and intravenous anesthetics
;inhibit the  acetylcholine-stimulated release of endothelium-derived
;hyperpolarizing factor.
;[613..624]:substance:"anesthetics"
;[638..651]:substance:"acetylcholine"
;[674..716]:substance:"endothelium-derived hyperpolarizing factor"
(SENT
  (S
    (PP-LOC (IN:[553..555] In)
      (NP (DT:[557..560] the) (NN:[561..567] rabbit) (JJ:[568..575] carotid)
          (NN:[576..582] artery)))
    (NP-SBJ (CC:[583..587] both)
      (NP (JJ:[588..596] volatile)
        (NML-1 (-NONE-:[596..596] *P*)))
      (CC:[597..600] and)
      (NP (JJ:[601..612] intravenous)
        (NML-1 (NNS:[613..624] anesthetics))))
    (VP (VBP:[625..632] inhibit)
      (NP
        (NP (DT:[633..636] the)
          (ADJP (NN:[638..651] acetylcholine) (HYPH:[651..652] -)
                (VBN:[652..662] stimulated))
          (NN:[663..670] release))
        (PP (IN:[671..673] of)
          (NP
            (ADJP (NN:[674..685] endothelium) (HYPH:[685..686] -)
                  (VBN:[686..693] derived))
            (VBG:[694..709] hyperpolarizing) (NN:[710..716] factor)))))
    (.:[716..717] .)))

;sentence 7 Span:719..1105
;Because the release of this factor may help to maintain vascular tone in
;humans  under conditions of a failing nitric oxide synthesis, e.g., in
;atherosclerosis,  the effects of two intravenous anesthetics, thiopental and
;etomidate, on the  endothelium-derived hyperpolarizing factor-mediated
;relaxant response to  acetylcholine were investigated in human isolated renal
;artery segments.
;[747..753]:substance:"factor"
;[830..842]:substance:"nitric oxide"
;[912..923]:substance:"anesthetics"
;[925..935]:substance:"thiopental"
;[940..949]:substance:"etomidate"
;[959..1001]:substance:"endothelium-derived hyperpolarizing factor"
;[1011..1019]:substance:"relaxant"
;[1033..1046]:substance:"acetylcholine"
(SENT
  (S
    (SBAR-PRP (IN:[719..726] Because)
      (S
        (NP-SBJ
          (NP (DT:[727..730] the) (NN:[731..738] release))
          (PP (IN:[739..741] of)
            (NP (DT:[742..746] this) (NN:[747..753] factor))))
        (VP (MD:[754..757] may)
          (VP (VB:[758..762] help)
            (VP (TO:[763..765] to)
              (VP (VB:[766..774] maintain)
                (NP (JJ:[775..783] vascular) (NN:[784..788] tone))
                (PP (IN:[789..791] in)
                  (NP (NNS:[792..798] humans)))
                (PP (IN:[800..805] under)
                  (NP
                    (NP (NNS:[806..816] conditions))
                    (PP (IN:[817..819] of)
                      (NP (DT:[820..821] a) (VBG:[822..829] failing)
                        (NML (JJ:[830..836] nitric) (NN:[837..842] oxide))
                        (NN:[843..852] synthesis)))
                    (,:[852..853] ,)
                    (PP (FW:[854..858] e.g.) (,:[858..859] ,)
                      (PP (IN:[860..862] in)
                        (NP (NN:[863..878] atherosclerosis))))))))))))
    (,:[878..879] ,)
    (NP-SBJ-1
      (NP (DT:[881..884] the) (NNS:[885..892] effects))
      (PP (IN:[893..895] of)
        (NP
          (NP (CD:[896..899] two) (JJ:[900..911] intravenous)
              (NNS:[912..923] anesthetics))
          (,:[923..924] ,)
          (NP (NN:[925..935] thiopental) (CC:[936..939] and)
              (NN:[940..949] etomidate))))
      (,:[949..950] ,)
      (PP (IN:[951..953] on)
        (NP
          (NP (DT:[954..957] the)
            (ADJP (NN:[959..970] endothelium) (HYPH:[970..971] -)
                  (VBN:[971..978] derived))
            (ADJP
              (NML (VBG:[979..994] hyperpolarizing) (NN:[995..1001] factor))
              (HYPH:[1001..1002] -) (VBN:[1002..1010] mediated))
            (JJ:[1011..1019] relaxant) (NN:[1020..1028] response))
          (PP (TO:[1029..1031] to)
            (NP (NN:[1033..1046] acetylcholine))))))
    (VP (VBD:[1047..1051] were)
      (VP (VBN:[1052..1064] investigated)
        (NP-1 (-NONE-:[1064..1064] *))
        (PP-LOC (IN:[1065..1067] in)
          (NP (JJ:[1068..1073] human) (VBN:[1074..1082] isolated)
            (NML (JJ:[1083..1088] renal) (NN:[1089..1095] artery))
            (NNS:[1096..1104] segments)))))
    (.:[1104..1105] .)))

;sentence 8 Span:1107..1115
;METHODS:
(SENT
  (NP (NNS:[1107..1114] METHODS) (::[1114..1115] :)))

;sentence 9 Span:1116..1301
;The segments were suspended in Krebs-Henseleit solution (37 degrees C) 
;containing the cyclooxygenase inhibitor diclofenac (1 microM) and
;preconstricted  with norepinephrine (6 microM).
;[1173..1175]:quantitative-value:"37"
;[1176..1185]:quantitative-units:"degrees C"
;[1203..1217]:substance:"cyclooxygenase"
;[1218..1227]:substance:"inhibitor"
;[1228..1238]:substance:"diclofenac"
;[1240..1241]:quantitative-value:"1"
;[1242..1248]:quantitative-units:"microM"
;[1275..1289]:substance:"norepinephrine"
;[1291..1292]:quantitative-value:"6"
;[1293..1299]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1 (DT:[1116..1119] The) (NNS:[1120..1128] segments))
    (VP (VBD:[1129..1133] were)
      (VP
        (VP (VBN:[1134..1143] suspended)
          (NP-1 (-NONE-:[1143..1143] *))
          (PP-LOC (IN:[1144..1146] in)
            (NP
              (NP
                (NP
                  (NML (NNP:[1147..1152] Krebs) (HYPH:[1152..1153] -)
                       (NNP:[1153..1162] Henseleit))
                  (NN:[1163..1171] solution))
                (PRN (-LRB-:[1172..1173] -LRB-)
                  (NP (CD:[1173..1175] 37)
                     (NNS:[1176..1183] degrees) (JJ:[1184..1185] C))
                  (-RRB-:[1185..1186] -RRB-)))
              (VP (VBG:[1188..1198] containing)
                (NP
                  (NP
                    (NP (DT:[1199..1202] the) (NN:[1203..1217] cyclooxygenase)
                        (NN:[1218..1227] inhibitor))
                    (NP (NN:[1228..1238] diclofenac)))
                  (PRN (-LRB-:[1239..1240] -LRB-)
                    (NP (CD:[1240..1241] 1) (NN:[1242..1248] microM))
                    (-RRB-:[1248..1249] -RRB-)))))))
        (CC:[1250..1253] and)
        (VP (VBN:[1254..1268] preconstricted)
          (NP-1 (-NONE-:[1268..1268] *))
          (PP-MNR (IN:[1270..1274] with)
            (NP
              (NP (NN:[1275..1289] norepinephrine))
              (PRN (-LRB-:[1290..1291] -LRB-)
                (NP (CD:[1291..1292] 6) (NN:[1293..1299] microM))
                (-RRB-:[1299..1300] -RRB-)))))))
    (.:[1300..1301] .)))

;sentence 10 Span:1302..1549
;Relaxations caused by acetylcholine (1 microM)  were compared in the presence
;and absence of the nitric oxide synthase inhibitor  N(G)-nitro-L-arginine
;(0.1 mM) in control segments and in segments exposed to  etomidate or
;thiopental (0.03-0.3 mM).
;[1324..1337]:substance:"acetylcholine"
;[1339..1340]:quantitative-value:"1"
;[1341..1347]:quantitative-units:"microM"
;[1399..1420]:substance:"nitric oxide synthase"
;[1421..1430]:substance:"inhibitor"
;[1432..1453]:substance:"N(G)-nitro-L-arginine"
;[1455..1458]:quantitative-value:"0.1"
;[1459..1461]:quantitative-units:"mM"
;[1511..1520]:substance:"etomidate"
;[1524..1534]:substance:"thiopental"
;[1536..1544]:quantitative-value:"0.03-0.3"
;[1545..1547]:quantitative-units:"mM"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[1302..1313] Relaxations))
      (VP (VBN:[1314..1320] caused)
        (NP (-NONE-:[1320..1320] *))
        (PP (IN:[1321..1323] by)
          (NP-LGS
            (NP (NN:[1324..1337] acetylcholine))
            (PRN (-LRB-:[1338..1339] -LRB-)
              (NP (CD:[1339..1340] 1) (NN:[1341..1347] microM))
              (-RRB-:[1347..1348] -RRB-))))))
    (VP (VBD:[1350..1354] were)
      (VP (VBN:[1355..1363] compared)
        (NP-1 (-NONE-:[1363..1363] *))
        (PP-LOC (IN:[1364..1366] in)
          (NP
            (NP (DT:[1367..1370] the) (NN:[1371..1379] presence)
                (CC:[1380..1383] and) (NN:[1384..1391] absence))
            (PP (IN:[1392..1394] of)
              (NP
                (NP
                  (NP (DT:[1395..1398] the)
                    
                    (NML (JJ:[1399..1405] nitric) (NN:[1406..1411] oxide))
                    (NN:[1412..1420] synthase)
                    (NN:[1421..1430] inhibitor))
                  (NP (NN:[1432..1453] N-LRB-G-RRB--nitro-L-arginine)))
                (PRN (-LRB-:[1454..1455] -LRB-)
                  (NP (CD:[1455..1458] 0.1) (NN:[1459..1461] mM))
                  (-RRB-:[1461..1462] -RRB-))))))
        (PP
          (PP (IN:[1463..1465] in)
            (NP (NN:[1466..1473] control) (NNS:[1474..1482] segments)))
          (CC:[1483..1486] and)
          (PP (IN:[1487..1489] in)
            (NP
              (NP (NNS:[1490..1498] segments))
              (VP (VBN:[1499..1506] exposed)
                (NP (-NONE-:[1506..1506] *))
                (PP (TO:[1507..1509] to)
                  (NP
                    (NP (NN:[1511..1520] etomidate) (CC:[1521..1523] or)
                        (NN:[1524..1534] thiopental))
                    (PRN (-LRB-:[1535..1536] -LRB-)
                      (NP
                        (QP (CD:[1536..1540] 0.03) (HYPH:[1540..1541] -)
                            (CD:[1541..1544] 0.3))
                        (NN:[1545..1547] mM))
                      (-RRB-:[1547..1548] -RRB-))))))))))
    (.:[1548..1549] .)))

;sentence 11 Span:1550..1735
;In addition, the effects of the two  anesthetics on the relaxant response to
;the nitric oxide donors glyceryl  trinitrate (3 microM) and sodium
;nitroprusside (0.1 microM) were examined.
;[1587..1598]:substance:"anesthetics"
;[1631..1650]:substance:"nitric oxide donors"
;[1651..1671]:substance:"glyceryl  trinitrate"
;[1673..1674]:quantitative-value:"3"
;[1675..1681]:quantitative-units:"microM"
;[1687..1707]:substance:"sodium nitroprusside"
;[1709..1712]:quantitative-value:"0.1"
;[1713..1719]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[1550..1552] In)
      (NP (NN:[1553..1561] addition)))
    (,:[1561..1562] ,)
    (NP-SBJ-1
      (NP (DT:[1563..1566] the) (NNS:[1567..1574] effects))
      (PP (IN:[1575..1577] of)
        (NP (DT:[1578..1581] the) (CD:[1582..1585] two)
            (NNS:[1587..1598] anesthetics)))
      (PP (IN:[1599..1601] on)
        (NP
          (NP (DT:[1602..1605] the) (JJ:[1606..1614] relaxant)
              (NN:[1615..1623] response))
          (PP (TO:[1624..1626] to)
            (NP
              (NP (DT:[1627..1630] the)
                
                (NML (JJ:[1631..1637] nitric) (NN:[1638..1643] oxide))
                (NNS:[1644..1650] donors))
              (NP
                (NP
                  (NP (NN:[1651..1659] glyceryl) (NN:[1661..1671] trinitrate))
                  (PRN (-LRB-:[1672..1673] -LRB-)
                    (NP (CD:[1673..1674] 3) (NN:[1675..1681] microM))
                    (-RRB-:[1681..1682] -RRB-)))
                (CC:[1683..1686] and)
                (NP
                  (NP (NN:[1687..1693] sodium) (NN:[1694..1707] nitroprusside))
                  (PRN (-LRB-:[1708..1709] -LRB-)
                    (NP (CD:[1709..1712] 0.1) (NN:[1713..1719] microM))
                    (-RRB-:[1719..1720] -RRB-)))))))))
    (VP (VBD:[1721..1725] were)
      (VP (VBN:[1726..1734] examined)
        (NP-1 (-NONE-:[1734..1734] *))))
    (.:[1734..1735] .)))

;sentence 12 Span:1737..1745
;RESULTS:
(SENT
  (NP (NNS:[1737..1744] RESULTS) (::[1744..1745] :)))

;sentence 13 Span:1746..2006
;The relaxant response to acetylcholine, which was resistant to both  nitric
;oxide synthase and cyclooxygenase blockade, was markedly reduced by the  K+Ca
;channel antagonist tetrabutyl ammonium (3 mM) and the cytochrome P450 
;inhibitor clotrimazole (30 microM).
;[1771..1784]:substance:"acetylcholine"
;[1815..1836]:substance:"nitric oxide synthase"
;[1841..1855]:substance:"cyclooxygenase"
;[1895..1896]:substance:"K"
;[1897..1899]:substance:"Ca"
;[1908..1918]:substance:"antagonist"
;[1919..1938]:substance:"tetrabutyl ammonium"
;[1940..1941]:quantitative-value:"3"
;[1942..1944]:quantitative-units:"mM"
;[1954..1969]:cyp450:"cytochrome P450"
;[1971..1980]:substance:"inhibitor"
;[1981..1993]:substance:"clotrimazole"
;[1995..1997]:quantitative-value:"30"
;[1998..2004]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1746..1749] The) (JJ:[1750..1758] relaxant)
          (NN:[1759..1767] response))
      (PP (TO:[1768..1770] to)
        (NP
          (NP (NN:[1771..1784] acetylcholine))
          (,:[1784..1785] ,)
          (SBAR
            (WHNP-1 (WDT:[1786..1791] which))
            (S
              (NP-SBJ-1 (-NONE-:[1791..1791] *T*))
              (VP (VBD:[1792..1795] was)
                (ADJP-PRD (JJ:[1796..1805] resistant)
                  (PP (TO:[1806..1808] to)
                    (NP (CC:[1809..1813] both)
                      (NP
                        (NML (JJ:[1815..1821] nitric) (NN:[1822..1827] oxide))
                        (NN:[1828..1836] synthase))
                      (CC:[1837..1840] and)
                      (NP (NN:[1841..1855] cyclooxygenase)
                          (NN:[1856..1864] blockade)))))))))))
    (,:[1864..1865] ,)
    (VP (VBD:[1866..1869] was)
      (ADVP (JJ:[1870..1878] markedly))
      (VP (VBN:[1879..1886] reduced)
        (NP-2 (-NONE-:[1886..1886] *))
        (PP-MNR (IN:[1887..1889] by)
          (NP
            (NP
              (NP
                (NML (DT:[1890..1893] the)
                  (NML (NN:[1895..1899] K+Ca) (NN:[1900..1907] channel))
                  (NN:[1908..1918] antagonist))
                 (NN:[1919..1929] tetrabutyl) (NN:[1930..1938] ammonium))
              (PRN (-LRB-:[1939..1940] -LRB-)
                (NP (CD:[1940..1941] 3) (NN:[1942..1944] mM))
                (-RRB-:[1944..1945] -RRB-)))
            (CC:[1946..1949] and)
            (NP
              (NP
                (NP (DT:[1950..1953] the)
                  (NML (NN:[1954..1964] cytochrome) (NN:[1965..1969] P450))
                  (NN:[1971..1980] inhibitor))
                (NP (NN:[1981..1993] clotrimazole)))
              (PRN (-LRB-:[1994..1995] -LRB-)
                (NP (CD:[1995..1997] 30) (NN:[1998..2004] microM))
                (-RRB-:[2004..2005] -RRB-)))))))
    (.:[2005..2006] .)))

;sentence 14 Span:2007..2263
;Both etomidate and thiopental, at a  concentration of 0.3 mM, selectively
;attenuated the relaxant response to  acetylcholine in
;N(G)-nitro-L-arginine-treated segments, but did not affect  relaxations
;elicited by glyceryl trinitrate or sodium nitroprusside.
;[2012..2021]:substance:"etomidate"
;[2026..2036]:substance:"thiopental"
;[2061..2064]:quantitative-value:"0.3"
;[2065..2067]:quantitative-units:"mM"
;[2118..2131]:substance:"acetylcholine"
;[2135..2156]:substance:"N(G)-nitro-L-arginine"
;[2219..2238]:substance:"glyceryl trinitrate"
;[2242..2262]:substance:"sodium nitroprusside"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2007..2011] Both) (NN:[2012..2021] etomidate)
          (CC:[2022..2025] and) (NN:[2026..2036] thiopental))
      (,:[2036..2037] ,)
      (PP (IN:[2038..2040] at)
        (NP
          (NP (DT:[2041..2042] a) (NN:[2044..2057] concentration))
          (PP (IN:[2058..2060] of)
            (NP (CD:[2061..2064] 0.3) (NN:[2065..2067] mM))))))
    (,:[2067..2068] ,)
    (VP
      (VP
        (ADVP (RB:[2069..2080] selectively))
        (VBD:[2081..2091] attenuated)
        (NP
          (NP (DT:[2092..2095] the) (JJ:[2096..2104] relaxant)
              (NN:[2105..2113] response))
          (PP (TO:[2114..2116] to)
            (NP (NN:[2118..2131] acetylcholine))))
        (PP-LOC (IN:[2132..2134] in)
          (NP
            (ADJP (NN:[2135..2156] N-LRB-G-RRB--nitro-L-arginine)
                  (HYPH:[2156..2157] -) (VBN:[2157..2164] treated))
            (NNS:[2165..2173] segments))))
      (,:[2173..2174] ,) (CC:[2175..2178] but)
      (VP (VBD:[2179..2182] did) (RB:[2183..2186] not)
        (VP (VB:[2187..2193] affect)
          (NP
            (NP (NNS:[2195..2206] relaxations))
            (VP (VBN:[2207..2215] elicited)
              (NP (-NONE-:[2215..2215] *))
              (PP (IN:[2216..2218] by)
                (NP-LGS
                  (NP (NN:[2219..2227] glyceryl) (NN:[2228..2238] trinitrate))
                  (CC:[2239..2241] or)
                  (NP (NN:[2242..2248] sodium) (NN:[2249..2262] nitroprusside)))))))))
    (.:[2262..2263] .)))

;sentence 15 Span:2265..2277
;CONCLUSIONS:
(SENT
  (NP (NNS:[2265..2276] CONCLUSIONS) (::[2276..2277] :)))

;sentence 16 Span:2278..2540
;Etomidate and thiopental inhibit the endothelium-derived  hyperpolarizing
;factor-mediated relaxant response to acetylcholine in the human  renal
;artery, an effect that appears to be attributable to the cytochrome 
;P450-inhibiting properties of these anesthetics.
;[2278..2287]:substance:"Etomidate"
;[2292..2302]:substance:"thiopental"
;[2315..2358]:substance:"endothelium-derived  hyperpolarizing factor"
;[2389..2402]:substance:"acetylcholine"
;[2480..2496]:cyp450:"cytochrome  P450"
;[2528..2539]:substance:"anesthetics"
(SENT
  (S
    (NP-SBJ (NN:[2278..2287] Etomidate) (CC:[2288..2291] and)
            (NN:[2292..2302] thiopental))
    (VP (VBP:[2303..2310] inhibit)
      (NP
        (NP (DT:[2311..2314] the)
          (ADJP (NN:[2315..2326] endothelium) (HYPH:[2326..2327] -)
                (VBN:[2327..2334] derived))
          (ADJP
            (NML (VBG:[2336..2351] hyperpolarizing) (NN:[2352..2358] factor))
            (HYPH:[2358..2359] -) (VBN:[2359..2367] mediated))
          (JJ:[2368..2376] relaxant) (NN:[2377..2385] response))
        (PP (TO:[2386..2388] to)
          (NP (NN:[2389..2402] acetylcholine))))
      (PP-LOC (IN:[2403..2405] in)
        (NP (DT:[2406..2409] the) (JJ:[2410..2415] human)
            (JJ:[2417..2422] renal) (NN:[2423..2429] artery)))
      (,:[2429..2430] ,)
      (NP-ADV
        (NP (DT:[2431..2433] an) (NN:[2434..2440] effect))
        (SBAR
          (WHNP-1 (WDT:[2441..2445] that))
          (S
            (NP-SBJ-1 (-NONE-:[2445..2445] *T*))
            (VP (VBZ:[2446..2453] appears)
              (S
                (NP-SBJ-1 (-NONE-:[2453..2453] *))
                (VP (TO:[2454..2456] to)
                  (VP (VB:[2457..2459] be)
                    (ADJP-PRD (JJ:[2460..2472] attributable)
                      (PP (TO:[2473..2475] to)
                        (NP
                          (NP (DT:[2476..2479] the)
                            (ADJP
                              (NML (NN:[2480..2490] cytochrome)
                                   (NN:[2492..2496] P450))
                              (HYPH:[2496..2497] -)
                               (VBG:[2497..2507] inhibiting))
                            (NNS:[2508..2518] properties))
                          (PP (IN:[2519..2521] of)
                            (NP (DT:[2522..2527] these)
                                (NNS:[2528..2539] anesthetics))))))))))))))
    (.:[2539..2540] .)))

;section 17 Span:2544..2588
;PMID: 8669690 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2544..2548] PMID) (::[2548..2549] :) (CD:[2550..2557] 8669690)
        (NN:[2558..2559] -LSB-) (NNP:[2559..2565] PubMed) (::[2566..2567] -)
        (NN:[2568..2575] indexed) (IN:[2576..2579] for)
        (NNP:[2580..2588] MEDLINE-RSB-)))
